- The rapidly expanding nanomedicine and advanced drug-delivery market is attracting growing attention as pharmaceutical companies seek ways to improve therapeutic performance without relying solely on costly new drug discovery programs.
- By addressing challenges such as poor bioavailability, inconsistent pharmacokinetics and limited tumor penetration, nanotechnology-based delivery systems may unlock additional value from existing oncology drugs.
- Oncotelic Therapeutics’ Deciparticle(TM) platform and Sapu003 program illustrate how innovative drug delivery approaches could help reshape the future of cancer treatment.
The search for new cancer therapies has traditionally focused on discovering entirely new drug candidates. While this approach has produced important breakthroughs, it is also expensive, time-consuming and carries a high risk of failure. Increasingly, researchers and biotechnology companies are exploring a complementary strategy: improving the way existing drugs are delivered to patients.
This shift is helping fuel rapid growth in the nanomedicine and advanced drug-delivery sector, which is projected to reach approximately $410 billion by 2030. Rather than starting from scratch, nanomedicine seeks to enhance the performance of proven therapeutic compounds by improving their stability, targeting capabilities and overall effectiveness.
The opportunity is particularly compelling in oncology. Many cancer therapies are administered orally, a route that can present several challenges including poor bioavailability, inconsistent pharmacokinetics, limited tumor penetration and the potential for treatment resistance. Even highly effective compounds can see their therapeutic potential constrained by these delivery limitations.
Nanotechnology-based delivery systems are designed to overcome many of these obstacles. By improving how drugs are absorbed, distributed and delivered to tumor sites, researchers hope to increase efficacy while reducing unwanted side effects and treatment variability.
One company pursuing this strategy is Oncotelic Therapeutics Inc. (OTCQB: OTLC), a clinical-stage biopharmaceutical company focused on developing novel oncology solutions. The company’s proprietary Deciparticle(TM) platform utilizes nanoparticle engineering to reformulate hydrophobic drugs into intravenously administered nanoparticle therapies designed to improve delivery performance.
A key example is Sapu003, Oncotelic’s intravenous nanoparticle formulation of Everolimus, a widely used oncology drug. According to the company, the reformulation is designed to achieve near-complete bioavailability while improving tumor targeting and reducing toxicity. Oncotelic believes these improvements may help shift treatment outcomes beyond simply slowing tumor growth and toward more effective cancer cell destruction.
The potential implications extend beyond clinical performance. Successfully enhancing the delivery of existing drugs may create opportunities to extend product utility, improve patient outcomes and generate additional commercial value from compounds that have already demonstrated therapeutic relevance.
As interest in precision medicine and targeted oncology continues to grow, drug delivery technologies are increasingly being viewed as more than supporting tools. Instead, they are emerging as a critical layer of innovation that may help unlock the next generation of value creation in cancer therapeutics. For companies like Oncotelic Therapeutics, the ability to optimize how drugs reach and interact with tumors could prove just as important as discovering entirely new compounds.
For more information, visit the company’s website at www.Oncotelic.com.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at ibn.fm/OTLC
